Shots:
- Under the existing collaboration agreement, Takeda has exercised an option to co-develop and co-commercialize DNL593 (PTV: PGRN) as brain-penetrant progranulin replacement therapy for the treatment of FTD-GRN
- In Jan 2018, Takeda entered into a collaboration agreement with Denali in which Takeda got an option for three programs including PTV: PGRN & obtains the right to develop and commercialize DNL593
- Denali receives an option fee and milestone upon achievement of clinical, regulatory & sales-based milestones. Both companies will share the development and commercialization costs and profits
Click here to read full press release/ article | Ref: Globenewswire | Image: Takeda
The post Takeda Exercises its Option with Denali to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin first appeared on PharmaShots.
